Bujar et al 2020 – A Process for Evaluating Quality Decision-Making Practices

Background: The development of a medicine is not only underpinned by good science but also by Quality Decision-Making Practices (QDMPs). Indeed, it is important to ensure that all organisations [...]

2021-01-19T09:53:24+00:00July 15th, 2020|Tags: , , |

Mashaki Ceyhan et al 2020 – Patients’ perspectives of the pharmaceutical regulatory and reimbursement system in Istanbul, Turkey

The aim of this study was to explore patients’ knowledge and perspectives in Istanbul, Turkey about the pharmaceutical regulatory review and reimbursement processes with respect to access to new [...]

CIRS RD Briefing 73 – HTA outcomes 2014-18

Timely recommendation for drug reimbursement by health technology assessment (HTA) agencies is critical to ensure that patient access to medicines of therapeutic value is not delayed. As part of an [...]

2021-01-19T11:10:10+00:00July 10th, 2019|Tags: |

Bujar et al 2019 – Quality decision making in Health Technology Assessment

Background: To evaluate the quality of the decision-making processes of pharmaceutical companies during medicines development for evidence generation to support reimbursement of new medicines and the appraisal recommendation decision-making process [...]

2021-01-18T17:07:01+00:00March 4th, 2019|Tags: , |

Bujar et al 2019 – Reliability and relevance of a decision-making instrument

Introduction: The Quality of Decision-Making Orientation Scheme (QoDoS) was developed to provide organisations involved in submission, approval and reimbursement of new medicines with a tool to improve the quality [...]

2021-01-18T17:04:02+00:00January 31st, 2019|Tags: , , |

CIRS RD Briefing 69: Review of HTA outcomes and timelines 2014-2017

Timely recommendation for drug reimbursement by health technology assessment (HTA) agencies is critical to ensure that patient access to medicines of therapeutic value is not delayed. As part of [...]

2021-01-22T11:58:11+00:00August 11th, 2018|Tags: |

CIRS RD Briefing 68: Regulatory and HTA decision making and access to medicines – the consequences of sequence

Historically, every jurisdiction with some form of regulatory agency capacity has undertaken the review of medicines as a first step in the market access process. This step is intended [...]